Franklin Resources Inc. Buys 31,984 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Franklin Resources Inc. grew its stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 4.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 738,090 shares of the company's stock after purchasing an additional 31,984 shares during the period. Franklin Resources Inc. owned about 1.29% of Structure Therapeutics worth $20,017,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in GPCR. ANTIPODES PARTNERS Ltd boosted its position in Structure Therapeutics by 115.0% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock valued at $28,000 after buying an additional 553 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Structure Therapeutics by 4,155.6% in the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock valued at $31,000 after acquiring an additional 1,122 shares during the last quarter. FNY Investment Advisers LLC acquired a new stake in shares of Structure Therapeutics during the 4th quarter valued at $40,000. Assetmark Inc. raised its position in Structure Therapeutics by 72.3% in the fourth quarter. Assetmark Inc. now owns 2,271 shares of the company's stock valued at $62,000 after purchasing an additional 953 shares during the last quarter. Finally, Jones Financial Companies Lllp raised its holdings in Structure Therapeutics by 29.8% in the 4th quarter. Jones Financial Companies Lllp now owns 4,228 shares of the company's stock valued at $115,000 after buying an additional 971 shares during the last quarter. 91.78% of the stock is owned by institutional investors.

Remove Ads

Analyst Ratings Changes

GPCR has been the topic of several analyst reports. HC Wainwright reissued a "buy" rating and issued a $80.00 price objective on shares of Structure Therapeutics in a research note on Thursday, December 19th. Stifel Nicolaus started coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They issued a "buy" rating and a $50.00 price target for the company. William Blair assumed coverage on Structure Therapeutics in a research note on Friday, February 28th. They issued an "outperform" rating on the stock. Finally, JMP Securities reiterated a "market outperform" rating and issued a $91.00 target price on shares of Structure Therapeutics in a report on Wednesday, December 18th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $81.29.

Structure Therapeutics Price Performance

Shares of NASDAQ GPCR traded up $0.85 during mid-day trading on Friday, reaching $15.90. 510,397 shares of the company's stock traded hands, compared to its average volume of 869,074. The business has a 50-day simple moving average of $20.98 and a 200 day simple moving average of $29.19. The stock has a market cap of $911.75 million, a P/E ratio of -21.49 and a beta of -1.35. Structure Therapeutics Inc. has a 1-year low of $13.22 and a 1-year high of $62.74.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.01. Equities research analysts anticipate that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.